Losartan Cost in Ohio (2026): Cash Prices, Medicaid, Insurance, and Discount Options

Losartan potassium is an oral angiotensin II receptor blocker (ARB), sold under the brand name Cozaar and, far more commonly today, as a generic tablet. It is FDA-approved for hypertension, for reducing stroke risk in patients with hypertension and left ventricular hypertrophy, and for slowing kidney disease progression in type 2 diabetes with nephropathy. It is not a controlled substance and has been available generically since patent expiration in 2010.

Generic losartan is one of the least expensive prescription drugs sold in the United States. For most Ohio residents, the real cost question is not "how cheap can it get" but which coverage lane applies: Ohio Medicaid, a commercial or Medicare Part D plan, or self-pay through a discount program. That decision, not the sticker price, determines what a given patient actually owes at the counter.

The core fact this page can support: generic losartan is a low-cost, first-line ARB that is preferred or Tier 1 on essentially every Ohio payer formulary, so out-of-pocket cost is usually driven by which coverage pathway a patient uses rather than by the drug's own price; specific dollar amounts change by pharmacy, plan year, and discount-card network and must be verified at the point of purchase rather than assumed from any published figure, including this one.

What losartan actually costs in Ohio

Nationally, generic losartan is consistently one of the cheapest antihypertensives on retail cash-pay price lists, and Ohio pharmacies are not an exception. Cash prices for a 30-day supply of generic losartan are commonly cited in the single-digit to low-teens dollar range, with variation by dose strength, pharmacy chain, and quantity dispensed. Brand-name Cozaar carries a materially higher manufacturer list price, but prescribers in Ohio and elsewhere overwhelmingly prescribe the generic, and list price is rarely what anyone pays.

Two things to verify locally rather than take from any article, including this one:

• The exact cash price at a specific Ohio pharmacy on a specific day, since chains adjust cash and discount-card pricing on their own schedules.
• Whether a discount card price or an insurance copay is lower for a given plan year. For a drug this inexpensive, cash-pay with a discount card sometimes beats an insurance copay, and a pharmacist can run both prices before the transaction is finalized.

Because pricing is volatile and no dated primary source in this review confirms a specific number for 2026, treat any single dollar figure as a starting point for a conversation with the pharmacist, not a guarantee.

Does Ohio Medicaid cover losartan?

Ohio Medicaid covers losartan for its FDA-approved indications: hypertension, stroke-risk reduction in patients with left ventricular hypertrophy, and diabetic nephropathy in type 2 diabetes, per the FDA prescribing information. Generic ARBs like losartan are typically placed as preferred, Tier 1 medications by Ohio's managed Medicaid plans, which generally means the lowest available copay tier for a generic.

Coverage details that vary by plan and change over time should be verified directly rather than assumed:

• Whether prior authorization applies if losartan is prescribed solely for a diabetes-related indication without a documented hypertension or nephropathy diagnosis.
• The current copay amount, which can range from $0 up to a small fixed fee depending on the specific managed care plan or the fee-for-service Unified Preferred Drug List.
• Which of Ohio's managed Medicaid plans (the roster includes several statewide MCOs) a given beneficiary is enrolled in, since formulary tiers are set at the plan level, not statewide.

Ohio's Medicaid program and its managed care organizations publish current preferred drug lists; a beneficiary or prescriber should check the specific plan's list for the current plan year rather than rely on a prior year's terms.

Insurance coverage beyond Medicaid

Commercial insurers and Medicare Part D plans available in Ohio generally place generic losartan on their lowest generic tier, consistent with its status as a first-line, inexpensive ARB. Under the Medicare Part D redesign, the annual out-of-pocket cap for covered Part D drugs took full effect in 2025, which limits total yearly drug spending for beneficiaries regardless of how many medications they take; details of how that cap applies to any individual's plan should be confirmed with CMS's Inflation Reduction Act Medicare page, since program parameters can be updated annually.

Employer-sponsored plans and pharmacy benefit managers vary in how much of a generic drug's low cost is passed to the patient as a $0 copay versus a small fixed fee. There is no single "Ohio" answer here; it is plan-specific and should be checked against the individual's benefit summary.

The evidence behind losartan as a preferred first-line ARB

Losartan's standing as a first-line antihypertensive rests substantially on a large, long-term randomized trial (commonly known by the acronym LIFE) that compared a losartan-based regimen to an atenolol-based regimen in older adults with hypertension and ECG evidence of left ventricular hypertrophy, reporting a reduction in a composite cardiovascular endpoint favoring losartan despite similar blood pressure control between arms. This is a real and influential trial, but the exact effect sizes, patient counts, and follow-up duration attributed to it in earlier drafts of this material could not be verified against a checked primary source during this review and should be confirmed against the original published trial report before being restated as precise figures.

Major hypertension guidelines typically recommend losartan and other ARBs as initial therapy, especially for patients experiencing ACE inhibitor side effects such as persistent cough or angioedema. Earlier guideline references on this page could not be confirmed as accurately representing their source materials and were therefore removed to avoid presenting unverified information. Before republishing any specific treatment targets or recommendations regarding losartan, a qualified medical professional should verify the current guideline language.

No direct quotation from a trial investigator is retained on this page. An earlier draft attributed a quotation to LIFE's lead investigator; that quotation could not be verified against a checked primary source and has been removed rather than presented as fact.

Compounded losartan in Ohio

Compounded losartan, such as a liquid suspension for a patient who cannot swallow tablets or a formulation avoiding a specific excipient allergy, can legally be prepared by a licensed 503A compounding pharmacy in Ohio under a valid patient-specific prescription. Ohio's State Board of Pharmacy regulates these facilities under Ohio Revised Code Chapter 4729, and federal oversight of compounding falls under the FDA's 503A framework, which prescribers and pharmacies can review directly with the FDA.

Compounding is a legitimate option for a genuine clinical need (pediatric dosing, documented allergy, swallowing difficulty), not a routine substitute for the commercially available tablet, which is already inexpensive and FDA-approved. Compounded preparations are not FDA-approved products in the way the manufactured tablet is; quality depends on the individual pharmacy's practices. Specific pricing for compounded losartan varies by pharmacy and is not something this review can state with a reliable number; ask the compounding pharmacy directly for current pricing and confirm it is licensed and in good standing with the Ohio Board of Pharmacy.

Discount programs and cash-pay options

Several widely available, non-Ohio-specific discount pathways commonly apply to generic losartan:

• Discount card platforms (such as GoodRx-style aggregators) route cash transactions through a contracted pharmacy benefit network at a negotiated rate, often producing a lower price than an uninsured cash price at the same pharmacy.
• Retail pharmacy generic programs, including flat-rate generic drug lists offered by large chains, frequently include losartan given its long generic history and low ingredient cost.
• Warehouse club pharmacies are open to non-members for prescription fills under federal law, and often price common generics competitively.
• Online cash-pay pharmacies that publish transparent markups over acquisition cost sometimes list losartan among their lowest-cost items.
• Patient assistance clearinghouses, such as NeedyMeds, can help identify manufacturer or state assistance programs for patients who qualify based on income.

None of the specific dollar figures sometimes advertised through these channels are stable enough to restate as fixed facts on a page like this one; they change by location, date, and promotional period. Confirm the current price directly with the pharmacy or program before assuming it applies.

Telehealth prescribing of losartan in Ohio

Ohio permits telehealth prescribing of non-controlled medications, including losartan, and the Ohio State Medical Board recognizes audio-video encounters as sufficient to establish a prescribing relationship for this class of drug. Because losartan is not a controlled substance, an in-person visit is not required in most circumstances to start therapy.

A telehealth evaluation for hypertension typically includes a review of blood pressure history, baseline labs (a basic metabolic panel checking kidney function and potassium before starting an ARB is standard practice), and a plan for follow-up monitoring, generally a repeat metabolic panel a few weeks after starting therapy along with home blood pressure checks. This is a description of common clinical practice, not a substitute for individualized medical advice from the prescribing clinician.

Dosing and monitoring: what is established, and what needs individualized judgment

Losartan for hypertension is typically started at a low-to-moderate dose and titrated based on blood pressure response, with lower starting doses used in patients with hepatic impairment or those on diuretics, per the FDA label. Blood pressure response generally begins within the first one to two weeks, with the full effect taking several weeks to appear.

Monitoring generally includes:

• Serum potassium, since ARBs can raise potassium levels, particularly in patients with reduced kidney function.
• Serum creatinine, where a modest rise after starting an ARB is expected and not automatically a reason to stop the drug, though a large rise warrants reassessment.
• Blood pressure, ideally tracked with a validated home monitor rather than office measurement alone.

Losartan interacts with potassium supplements, potassium-sparing diuretics, NSAIDs, and lithium; a pharmacist or prescriber should review a patient's full medication list before and after starting therapy. This page does not provide individualized dosing instructions; the correct starting dose, titration schedule, and monitoring interval depend on kidney function, other medications, and clinical judgment from the prescribing clinician.

What is established, what is plausible, and what needs verification

Established: Losartan is FDA-approved for hypertension, LVH-related stroke risk reduction, and diabetic nephropathy in type 2 diabetes. It is generically available and inexpensive relative to most prescription drugs. Ohio Medicaid and commercial payers in Ohio generally place generic ARBs, including losartan, on their lowest cost-sharing tier. Compounding of losartan by a licensed 503A pharmacy under a valid prescription is legal in Ohio. Telehealth prescribing of losartan is permitted in Ohio because it is a non-controlled medication.

Plausible but not independently confirmed in this review: The precise trial statistics historically cited for losartan's cardiovascular benefit versus atenolol, and specific guideline citation numbers, require confirmation against the original published sources before being restated as exact figures.

Not established by anything in this review: Any single, current dollar price for losartan at a named Ohio pharmacy, any specific county-level telehealth access statistic, and any specific enrollment count for Ohio Medicaid. These are the kinds of numbers that change often and were not independently verified here; treat them as unconfirmed until checked against a current, dated source.

Verification checklist: stable facts vs. facts that expire

Use this to separate what a reader can treat as durable from what must be re-checked before relying on it.

Stable (federal or clinical, unlikely to change month to month):

• Losartan's FDA-approved indications (hypertension, LVH stroke-risk reduction, diabetic nephropathy in type 2 diabetes), confirm against the current FDA label.
• Losartan is not a controlled substance.
• Generic losartan has been available since 2010 and multiple manufacturers supply the U.S. market, confirm current status in the FDA Orange Book.
• Compounding of losartan by a licensed 503A pharmacy is legal under a valid patient-specific prescription, governed by Ohio Revised Code Chapter 4729 and FDA's 503A framework.
• Standard monitoring parameters (potassium, creatinine, blood pressure) after starting an ARB.

Date-sensitive (must be re-verified before quoting a number):

• Cash price for a 30-day supply of generic losartan at a specific Ohio pharmacy, today.
• Whether a specific Ohio Medicaid managed care plan requires prior authorization for a given indication, this plan year.
• The exact copay tier and dollar amount under a specific commercial or Part D plan, this plan year.
• Current terms of the Medicare Part D annual out-of-pocket cap as it applies to a specific beneficiary's plan.
• Whether a named discount card, warehouse club, or online pharmacy is currently offering a specific advertised price.
• Licensing status and current pricing at any specific 503A compounding pharmacy.
• Whether a specific insurer currently reimburses telehealth visits at parity with in-person visits.

If a fact falls in the second list, do not treat any number in this article, or any other undated source, as current. Call the pharmacy, plan, or state agency directly.

Frequently asked questions

References

1. FDA. Cozaar (losartan potassium) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020386s062lbl.pdf
2. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). https://www.accessdata.fda.gov/scripts/cder/ob/
3. Ohio Revised Code, Chapter 4729 (Pharmacists; Pharmacies). https://codes.ohio.gov/ohio-revised-code/chapter-4729
4. Ohio State Medical Board. https://med.ohio.gov/
5. CMS. Inflation Reduction Act and Medicare. https://www.cms.gov/inflation-reduction-act-and-medicare
6. NeedyMeds patient assistance program directory. https://www.needymeds.org/

Note for editorial and medical review: earlier drafts of this page attributed specific trial statistics, a direct quotation, and several precise statewide counts (Medicaid enrollment, number of compounding pharmacies, county-level telehealth access) to sources that could not be verified during this pass. Those items have been removed or converted to hedged, general statements. A qualified reviewer with access to the primary trial publication and current Ohio Medicaid/plan documents should confirm any figure before it is restored with a specific number.